Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of dysthymia with sertraline: A double-blind, placebo-controlledtrial in dysthymic patients without major depression
Autore:
Ravindran, AV; Guelfi, JD; Lane, RM; Cassano, GB;
Indirizzi:
Pfizer Pharmaceut Grp, New York, NY 10017 USA Pfizer Pharmaceut Grp New York NY USA 10017 t Grp, New York, NY 10017 USA Univ Pisa, Inst Psychiat, I-56100 Pisa, Italy Univ Pisa Pisa Italy I-56100 iv Pisa, Inst Psychiat, I-56100 Pisa, Italy Univ Ottawa, Dept Psychiat, Ottawa, ON, Canada Univ Ottawa Ottawa ON Canada v Ottawa, Dept Psychiat, Ottawa, ON, Canada Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada Univ Ottawa Ottawa ON Canada Dept Cellular & Mol Med, Ottawa, ON, Canada Univ Paris 05, Clin Malad Mentales & Encephale, Paris, France Univ Paris 05 Paris France in Malad Mentales & Encephale, Paris, France
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 11, volume: 61, anno: 2000,
pagine: 821 - 827
SICI:
0160-6689(200011)61:11<821:TODWSA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMIPRAMINE; EFFICACY; PHENELZINE; DISORDER; PHARMACOTHERAPY; OUTPATIENTS; RITANSERIN; FLUOXETINE; SCALE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Lane, RM Pfizer Pharmaceut Grp, 235 E 42 St, New York, NY 10017 USA PfizerPharmaceut Grp 235 E 42 St New York NY USA 10017 10017 USA
Citazione:
A.V. Ravindran et al., "Treatment of dysthymia with sertraline: A double-blind, placebo-controlledtrial in dysthymic patients without major depression", J CLIN PSY, 61(11), 2000, pp. 821-827

Abstract

Background: The selective serotonin reuptake inhibitor sertraline has beenshown to be efficacious and well tolerated for the treatment of major depressive disorder. Relatively few trials, however, have examined the role of pharmacotherapy in dysthymia without concurrent major depression. The current investigation focuses on the use of sertraline for the treatment of dysthymia. Method: In this 12-week, multicenter, double-blind study, 310 patients with a DSM-III-R diagnosis of dysthymic disorder without concurrent major depression were randomly assigned to receive either sertraline (N = 158) or placebo (N = 152). Sertraline was initiated at a dose of 50 mg daily, with titration permitted to a maximum of 200 mg daily. The primary evaluation criteria were the Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder Version (SIGH-SAD), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinical Global impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales. Results: Mean percentage reductions for the intent-to-treat population in SIGH-SAD scores were 44.6% for the sertraline-treated group and 33.2% for the placebo-treated group (p = .03); MADRS scores, 43.6% and 33.0% (p = .02); and CGI-S scores, 32.8% and 22.8% (p = .02), A significantly greater proportion of the sertraline-treated group was classified as responders (defined for HAM-D and MADRS scores as a 50% score reduction and for CGI-I as a score of 1 or 2 by the final visit) and remitters (SIGH-SAD score less than or equal to 8) relative to the placebo-treated group by the final visit. In addition, sertraline-treated patients experienced greater improvements in all 9 domains of the Battelle Quality of Life Questionnaire than placebo-treated patients did, with a significant difference observed in favor of sertraline in 8 of the 9 domains. The life satisfaction and social interaction quality of life domains showed significantly greater response in sertraline responders compared with placebo SIGH-SAD responders. Sertraline was well tolerated. Thirteen percent of the sertraline-treated group versus 8% of theplacebo-treated group withdrew from therapy owing to adverse events (p = .14). Conclusion: Sertraline is efficacious and well tolerated in the short-termtreatment of dysthymia without concurrent major depression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 03:41:21